Details of Disease

General Information of Disease (ID: DIS6ZPAI)

• Disease Name: Adult hepatocellular carcinoma
• Synonyms: hepatocellular cancer; adult primary hepatocellular carcinoma; adult primary liver cell carcinoma; hepatocellular carcinoma of adults; adult primary carcinoma of the liver cell; adult hepatocellular carcinoma; adult primary hepatoma; adult hepatoma; adult HCC; adult primary carcinoma of liver cell
• Definition: Adult hepatocellular carcinoma is the most common primary liver cancer of adulthood. Derived from well-differentiated hepatocytes, it often develops from chronic liver cirrhosis which is most often due to hepatitis B and C virus or alcohol abuse. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure.
• Disease Hierarchy:
  DIS0J828: Hepatocellular carcinoma
  DIS6ZPAI: Adult hepatocellular carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0016216
  UMLS CUI: C0279607
  MedGen ID: 124633
  Orphanet ID: 210159
  SNOMED CT ID: 1197204009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Erlotinib	DMCMBHA	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 12 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CASP8	TT6SZNG	Limited	SomaticCausalMutation	[2]
EGF	TTED8JB	Limited	SusceptibilityMutation	[3]
KIF20B	TTQECT2	Limited	Biomarker	[4]
BLVRA	TTJBPN3	moderate	Altered Expression	[5]
AFP	TTCFEA1	Strong	Biomarker	[6]
ASAP3	TTB4ZEN	Strong	Altered Expression	[7]
ENPP2	TTSCIM2	Strong	Biomarker	[8]
GPC3	TTJTSX4	Strong	Altered Expression	[9]
LDHA	TTW76JE	Strong	Biomarker	[10]
OGFR	TT6IEYX	Strong	Biomarker	[11]
PNPLA3	TTEUAEH	Strong	Genetic Variation	[12]
SLC5A5	TTW7HI9	Strong	Biomarker	[13]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
MAT1A	DEQ6NC9	Strong	Biomarker	[14]
UGT1A9	DE85D2P	Strong	Genetic Variation	[15]

This Disease Is Related to 17 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
H2AZ1	OT3KJJNQ	Limited	Biomarker	[16]
PDGFRL	OTJPRECT	Limited	Genetic Variation	[17]
SOX1	OTVI1RAR	Limited	Posttranslational Modification	[18]
TSC1	OTFF4YZ7	Limited	Genetic Variation	[19]
TSC2	OT47LWI9	Limited	Genetic Variation	[19]
ALX4	OTNS9A29	moderate	Biomarker	[20]
AXIN1	OTRGZGZ5	Strong	Altered Expression	[21]
EIF3I	OTE07WND	Strong	Biomarker	[22]
ENC1	OTJEUB6U	Strong	Biomarker	[23]
MTG1	OTC9U1LI	Strong	Altered Expression	[7]
NCAPG	OT1AI9EO	Strong	Biomarker	[24]
NUDT6	OTCS3NYZ	Strong	Biomarker	[25]
PBX3	OT8WMVM4	Strong	Biomarker	[26]
PYCR1	OTQHB52T	Strong	Biomarker	[27]
SERPINB4	OT88LHZ8	Strong	Biomarker	[28]
SULF1	OTJCNCO0	Strong	Posttranslational Modification	[29]
SUV39H2	OTU0F4LL	Strong	Altered Expression	[30]

References

• [1] Erlotinib FDA Label
• [2] Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas.Oncogene. 2005 Jan 6;24(1):141-7. doi: 10.1038/sj.onc.1208244.
• [3] A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.Gastroenterology. 2011 Jul;141(1):141-9. doi: 10.1053/j.gastro.2011.03.045. Epub 2011 Mar 24.
• [4] Pseudopod-associated protein KIF20B promotes Gli1-induced epithelial-mesenchymal transition modulated by pseudopodial actin dynamic in human colorectal cancer.Mol Carcinog. 2018 Jul;57(7):911-925. doi: 10.1002/mc.22812. Epub 2018 Apr 10.
• [5] Predictive role BLVRA mRNA expression in hepatocellular cancer.Ann Hepatol. 2016 Nov-Dec 2016;15(6):881-887. doi: 10.5604/16652681.1222104.
• [6] Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.Cell Immunol. 2019 Jan;335:59-67. doi: 10.1016/j.cellimm.2018.10.011. Epub 2018 Nov 1.
• [7] DDEFL1 correlated with Rho GTPases activity in breast cancer.Oncotarget. 2017 Oct 26;8(68):112487-112497. doi: 10.18632/oncotarget.22095. eCollection 2017 Dec 22.
• [8] Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?.J Gastrointest Surg. 2007 Dec;11(12):1628-34; discussion 1634-5. doi: 10.1007/s11605-007-0322-9. Epub 2007 Sep 25.
• [9] Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.Med Sci Monit. 2017 Feb 16;23:850-855. doi: 10.12659/msm.899198.
• [10] The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer.Iran J Basic Med Sci. 2017 Feb;20(2):187-192. doi: 10.22038/ijbms.2017.8246.
• [11] The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.Am J Physiol Regul Integr Comp Physiol. 2010 Feb;298(2):R459-66. doi: 10.1152/ajpregu.00646.2009. Epub 2009 Nov 18.
• [12] PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.Semin Liver Dis. 2013 Nov;33(4):369-79. doi: 10.1055/s-0033-1358525. Epub 2013 Nov 12.
• [13] Dual-targeted NIS polyplexes-a theranostic strategy toward tumors with heterogeneous receptor expression.Gene Ther. 2019 Apr;26(3-4):93-108. doi: 10.1038/s41434-019-0059-6. Epub 2019 Jan 25.
• [14] Acetylation of MAT II represses tumour cell growth and is decreased in human hepatocellular cancer.Nat Commun. 2015 Apr 30;6:6973. doi: 10.1038/ncomms7973.
• [15] Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene.Gastroenterology. 2001 Nov;121(5):1136-44. doi: 10.1053/gast.2001.28655.
• [16] H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.Int J Oncol. 2018 Apr;52(4):1235-1245. doi: 10.3892/ijo.2018.4292. Epub 2018 Feb 28.
• [17] Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma.J Gastroenterol Hepatol. 2003 Apr;18(4):430-6. doi: 10.1046/j.1440-1746.2003.02997.x.
• [18] Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.Biochem Biophys Res Commun. 2013 Sep 20;439(2):187-90. doi: 10.1016/j.bbrc.2013.08.065. Epub 2013 Aug 29.
• [19] TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.Gut. 2017 Aug;66(8):1496-1506. doi: 10.1136/gutjnl-2016-312734. Epub 2016 Dec 14.
• [20] Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.Gastroenterology. 2006 Nov;131(5):1418-30. doi: 10.1053/j.gastro.2006.08.034. Epub 2006 Aug 18.
• [21] Alterations of axis inhibition protein 1 (AXIN1) in hepatitis B virus-related hepatocellular carcinoma and overexpression of AXIN1 induces apoptosis in hepatocellular cancer cells.Oncol Res. 2013;20(7):281-8. doi: 10.3727/096504013x13639794277608.
• [22] The translation initiation factor eIF3i up-regulates vascular endothelial growth factor A, accelerates cell proliferation, and promotes angiogenesis in embryonic development and tumorigenesis.J Biol Chem. 2014 Oct 10;289(41):28310-23. doi: 10.1074/jbc.M114.571356. Epub 2014 Aug 21.
• [23] Comprehensive study of tumour single nucleotide polymorphism array data reveals significant driver aberrations and disrupted signalling pathways in human hepatocellular cancer.IET Syst Biol. 2014 Apr;8(2):24-32. doi: 10.1049/iet-syb.2013.0027.
• [24] Non-SMC Condensin I Complex, Subunit G (NCAPG) is a Novel Mitotic Gene Required for Hepatocellular Cancer Cell Proliferation and Migration.Oncol Res. 2018 Mar 5;26(2):269-276. doi: 10.3727/096504017X15075967560980. Epub 2017 Oct 18.
• [25] Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition.Cancer Discov. 2019 Dec;9(12):1646-1649. doi: 10.1158/2159-8290.CD-19-1156.
• [26] MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma.Oncotarget. 2016 Jul 5;7(27):42461-42473. doi: 10.18632/oncotarget.9886.
• [27] PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.J Transl Med. 2019 Oct 16;17(1):343. doi: 10.1186/s12967-019-2091-0.
• [28] AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.BMC Cancer. 2008 Jul 18;8:200. doi: 10.1186/1471-2407-8-200.
• [29] hSulf-1 gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers.PLoS One. 2011;6(8):e23274. doi: 10.1371/journal.pone.0023274. Epub 2011 Aug 10.
• [30] The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.J Cancer. 2019 Jan 1;10(3):721-729. doi: 10.7150/jca.28254. eCollection 2019.